Highest-materiality recent filing
Alzamend Neuro announces death of director Lynne Fahey McGrath on July 20, 2026
Dr. Lynne Fahey McGrath, a director of Alzamend Neuro, passed away on July 20, 2026.
Alzamend Neuro annual meeting: all proposals pass, including reverse stock split up to 1:10
All seven director nominees elected, including William B. Horne, Milton C. Ault III, Stephan Jackman, Henry C. Nisser, Mark Gustafson, Lynne F. McGrath, Jeffrey Oram.
Alzamend Neuro receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum
Stockholders' equity reported at ~$2.2M as of Jan 31, 2026, below Nasdaq's $2.5M minimum requirement for continued listing.
Alzamend Neuro enters $3M at-the-market equity agreement with Ascendiant Capital
Up to $3.0M in common stock may be sold periodically via ATM offering with sole agent Ascendiant Capital Markets.
Alzamend Neuro director Andrew H. Woo, M.D., Ph.D. passed away on Nov. 14, 2025
Andrew H. Woo served as a director since the company's IPO in June 2021.
Alzamend Neuro eliminates Series B and Series C convertible preferred stock
Filed Certificates of Elimination for Series B and Series C convertible preferred stock with Delaware Secretary of State on October 14, 2025.
Alzamend Neuro issues 361,743 shares on Series B Preferred conversion
Between Oct 1-8, 2025, 361,743 shares issued upon conversion of ~839.2 Series B Convertible Preferred shares.
Alzamend Neuro issues 300,000 shares on conversion of Series B Preferred Stock
Issued 300,000 common shares upon conversion of 696 Series B Preferred shares between Sep 17-25, 2025.
Alzamend Neuro issues 243,429 common shares on conversion of Series B Preferred (Jul 23-30, 2025)
243,429 common shares issued upon conversion of ~564.76 shares of Series B Convertible Preferred Stock.
Alzamend Neuro FY2025 cash $3.9M, equity $3.9M; $5M financing completed ahead of schedule
Cash of $3.9M at April 30, 2025 vs $0.4M prior year; stockholder equity of $3.9M vs deficit $2.6M.
Alzamend Neuro eliminates Series A convertible preferred stock via Certificate of Elimination
Filed Certificate of Elimination with Delaware Secretary of State on July 9, 2025 to cancel Series A Preferred Stock.
Alzamend Neuro announces 1-for-9 reverse stock split effective May 12 to maintain Nasdaq listing
Shares outstanding reduce from ~7,208,591 to ~800,954 at 1-for-9 ratio.
Alzamend Neuro stockholders approve reverse stock split and Series C conversion at annual meeting
Elected eight directors including William B. Horne, Milton C. Ault III, and others with substantial support; broker non-votes of 2,270,160.
Alzamend Neuro amends bylaws to lower stockholder quorum to 35%, creates Series C Preferred Stock
Board reduced quorum for stockholder meetings from majority of outstanding shares to 35%.
Exchanges 97.75 Series A shares for 87.99 Series C shares; cancels existing 640K-share warrants.
Net cash from financing $8.3M for six months ended Oct 31, 2024; stockholder equity improved to $3.8M from a $2.6M deficit.
Alzamend Neuro regains Nasdaq compliance; avoids delisting
Received written notice from Nasdaq Hearings Panel on Oct 14, 2024 that it has regained compliance with minimum stockholders' equity rule ($2.5M required).
Alzamend Neuro enters ATM offering for up to $6.5M in common stock
Entered ATM Sales Agreement with Ascendiant Capital Markets for up to $6.5M of common stock.
Alzamend Neuro regains Nasdaq bid price compliance; MVLS deficiency still pending
Nasdaq notified Alzamend on July 30, 2024 that bid price compliance is regained after 10 consecutive days above $1.00.
Alzamend Neuro announces 1-for-10 reverse stock split to regain Nasdaq compliance
Reverse split effective July 16, 2024; reduces outstanding shares from ~7.98M to ~798K.
Stockholders approve conversion of Series A Preferred Stock for up to $25M financing
Proposal approved with 5,356,845 votes for, 79,371 against, 3,043 abstentions; no broker non-votes.
Alzamend Neuro gets Nasdaq extension to meet $2.5M equity rule by Sept 23, 2024
Nasdaq Hearings Panel granted continued listing on Capital Market, subject to compliance with Listing Rule 5550(b)(1).
Filed under Item 7.01 as a Regulation FD disclosure; presentation furnished as Exhibit 99.1.
Alzamend Neuro stockholders approve $6 million Series B transaction with Ault Lending
Stockholders approved issuance of up to 6,000 shares of Series B convertible preferred stock and warrants for 6,000,000 common shares at $6 million total.
Alzamend Neuro raises up to $25M via Series A Preferred and warrants; initial $500K closed
Up to $25 million financing via Series A Convertible Preferred Stock and warrants; initial tranche of $500,000 closed May 10, 2024.
Alzamend Neuro dismisses Baker Tilly as auditor, appoints Haskell & White
Audit Committee dismissed Baker Tilly US, LLP on May 5, 2024; no accounting disagreements.
Alzamend Neuro enters $25M financing via preferred stock and warrants at 15% dividend
Initial $500,000 closing of 50 Series A Preferred shares at $10,000 each; up to $25M total.
Alzamend Neuro terminates ATM equity program after raising ~$1.3M at ~$1.20/share
Terminated ATM agreement with Ascendiant Capital Markets effective May 16, 2024.
Alzamend Neuro annual meeting results: reverse split approved, Proposal 3 vote adjourned
All eight director nominees elected; Baker Tilly ratified as auditor for FY ending April 30, 2024.
Alzamend Neuro raises $400K via convertible preferred and short-term note
Sold 100 Series B preferred shares and warrants for 100K common shares to Ault Lending for $100K; total $2.1M of $6M facility drawn.
Alzamend Neuro faces Nasdaq delisting over MVLS; sells $780K Series B convertible to affiliate
Nasdaq notified ALZN it fails MVLS rule; delisting scheduled for April 4 unless appeal stays it.
Alzamend Neuro amends warrant and preferred stock designations to ensure equity classification
Entered warrant amendment with Ault Lending LLC to remove language that could prevent equity classification.
Alzamend Neuro files amended Series B preferred stock designation and eliminates Series A
Filed amended and restated certificate of designations for Series B preferred stock on March 1, 2024.
Alzamend Neuro raises up to $6M from affiliate, receives Nasdaq bid price deficiency notice
Entered up to $6M Series A convertible preferred stock sale to affiliate Ault Lending; initial $1.22M closed via cancellation of prior advances.
Alzamend Neuro appoints founder Milton C. Ault III as Vice Chairman and director
Appointment effective January 4, 2024; Ault founded the company in 2016 and previously served as Chairman.
Alzamend Neuro regains Nasdaq minimum bid price compliance
Received Nasdaq notice on Nov 15, 2023 confirming compliance with $1.00 minimum bid price rule.
Alzamend Neuro announces 1-for-15 reverse stock split to regain Nasdaq compliance
Reverse stock split at 1-for-15 ratio effective 12:01 AM ET on October 31, 2023.
Alzamend Neuro receives Nasdaq MVLS deficiency notice; stockholders approve reverse stock split
Nasdaq notice on Sep 26, 2023: MVLS below $35M for 30 consecutive business days.
Alzamend Neuro granted Nasdaq extension to Nov 15, 2023; must execute reverse stock split by Nov 1
Nasdaq Hearings Panel grants extension until Nov 15, 2023 to regain $1.00 minimum bid compliance.
Alzamend Neuro enters ATM equity facility for up to $9.8M with Ascendiant Capital
Entered Sales Agreement with Ascendiant Capital Markets for at-the-market issuance of common stock up to $9.8M.
Alzamend Neuro to use X and LinkedIn for material disclosures
Company adopts X (Twitter) @AlzamendNeuro and LinkedIn for public communications.
Alzamend Neuro receives Nasdaq delisting notice; hearing scheduled for Oct 12
Nasdaq notified Alzamend on Aug 1, 2023 it failed to regain compliance with $1 bid price rule.
Phase IIA multiple ascending dose study identified MTD of lithium carbonate equivalent 240 mg TID, unlikely to require lithium TDM.
Alzamend Neuro announces 2023 annual meeting voting results; all proposals pass
Elected directors: Horne, Jackman, Nisser, Gustafson, McGrath, Woo, Oram; each received >46.6M votes for.
Alzamend Neuro updates investor presentation for April 2023; no material new disclosures
Company furnished an updated corporate presentation (Exhibit 99.1) used for investor meetings.
Alzamend Neuro initiates Phase I/IIA trial of ALZN002 for mild to moderate Alzheimer's dementia
Initiated Phase I/IIA clinical trial of immunotherapy vaccine ALZN002 for mild to moderate Alzheimer's dementia.
Alzamend Neuro completes Phase IIA MAD trial for AL001; topline data due June 2023
Completed clinical portion of Phase IIA multiple ascending dose trial for AL001 in Alzheimer's dementia.
Alzamend Neuro Q3 net loss widens to $5.4M; cash $7.4M; clinical milestones on track
Net loss $5.4M ($0.06/share) vs $2.6M ($0.03/share) a year ago; R&D spend rose to $2.9M.
Alzamend Neuro receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq deficiency letter on Jan 30, 2023 for bid price below $1.00 for 30 consecutive days.
Alzamend Neuro updates corporate presentation; no material new details disclosed
Alzamend Neuro refreshed its investor presentation for meetings with investors and analysts.
Effective January 4, 2024, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), appointed Milton C. Ault, III as a director and Vice Chairman of its board of directors (the “ Board ”).
On August 5, 2022, the Company appointed David J. Katzoff, who has been serving as the Company’s Chief Operating Officer, as its new Chief Financial Officer.
On August 1, 2022, Lien Escalona resigned as the Chief Financial Officer of Alzamend Neuro, Inc. (the “Company”), effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material